Pharmacovigilance Market

Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • Rep Id : TMRGL1729
  • Published On : Mar 2015
  • No. of Pages : 151
  • Category : Pharmaceutical

 
Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation
 
Chapter 2 Executive Summary
 
Chapter 3 Global Pharmacovigilance Market Dynamics
3.1 Introduction
3.2 Market Drivers
      3.2.1 Increasing Consumption of Drugs Would Fuel Demand for Continuous Drug Event Monitoring
      3.2.2 Rise in the Cases of Adverse Drug Reactions and Drug Toxicity Would Boost Demand for Pharmacovigilance Activities
      3.2.3 Rise in Adoption of Outsourcing Services Expected to Accentuate the Market Growth
3.3 Market Restraints
      3.3.1 High Risk Associated with Data Security in Pharmacovigilance Outsourcing
      3.3.2 Lack of Availability of Skilled Labor might Hinder the Market Growth
      3.3.3 Inadequate Pharmacovigilance System for Herbal Products in Asia Pacific Might Hamper the Market Growth
3.4 Market Opportunities
      3.4.1 Huge Scope for Rapid Growth of Pharmacovigilance Market in Emerging Economies
      3.4.2 Shift in Preference for Outsourcing among Various Pharmaceutical and Life Sciences Companies
3.5 Porter’s Five Forces Analysis: Global Pharmacovigilance Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Bargaining Power of Buyers
      3.5.3 Threat of Substitutes
      3.5.4 Threat of New Entrants
      3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography
3.7 Competitive Landscape
      3.7.1 Market Share Analysis: Global Pharmacovigilance Market, 2013 (Value %)
 
Chapter 4 Global Pharmacovigilance Market, by Phases of Drug Development
4.1 Overview
      4.1.1 Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2012 – 2020 (USD Million)
      4.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Clinical Trial Phases, 2013 & 2020 (Value %)
4.2 Preclinical Studies
      4.2.1 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.3 Phase I
      4.3.1 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.4 Phase II
      4.4.1 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.5 Phase III
      4.5.1 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
4.6 Phase IV or Post Marketing Surveillance
      4.6.1 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 5 Global Pharmacovigilance Market, By Type of Methods
5.1 Overview
      5.1.1 Global Pharmacovigilance Market Revenue, by Type of Methods , 2012 – 2020 (USD Million)      
      5.1.2 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
5.3 Spontaneous Reporting
      5.3.1 Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.4 Intensified ADR Reporting
      5.4.1 Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD Million)
5.5 Targeted Spontaneous Reporting
      5.5.1 Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
5.6 Cohort Event Monitoring
      5.6.1 Global Cohort Event Monitoring Market Revenue, 2012 – 2020 (USD Million)
5.7 EHR Mining
      5.7.1 Global EHR Mining Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 6 Global Pharmacovigilance Market, by Type Service Providers
6.1 Overview
      6.1.1 Global Pharmacovigilance Market Revenue, by Type of Service Providers , 2012 – 2020 (USD Million)
      6.1.2 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
6.2 In-house Pharmacovigilance
      6.2.1 Global In-House Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
6.3 Contract Outsourcing
      6.3.1 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
 
Chapter 7 Global Pharmacovigilance Market, by Geography
7.1 Overview
      7.1.1 Global Pharmacovigilance Market Revenue, by Geography, 2012 – 2020 (USD Million)
7.2 North America
      7.2.1 North America Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.3 Europe
      7.3.1 Europe Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.4 Asia Pacific
      7.4.1 Asia Pacific Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
7.5 Rest of the World (RoW)
      7.5.1 RoW Pharmacovigilance Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 8 Recommendations
 
Chapter 9 Company Profiles
9.1 Accenture plc
      9.1.1 Company Overview
      9.1.2 Financial Overview
      9.1.3 Product Portfolio
      9.1.4 Business Strategies
      9.1.5 Recent Developments
9.2 Bristol-Myers Squibb
      9.2.1 Company Profile
      9.2.2 Financial Overview
      9.2.3 Product Portfolio
      9.2.4 Business Strategies
9.3 Clinquest Group B.V.
      9.3.1 Company Overview
      9.3.2 Financial Overview
      9.3.3 Product Portfolio
      9.3.4 Business Strategies
      9.3.5 Recent Developments
9.4 Cognizant Technology Solutions
      9.4.1 Company Overview
      9.4.2 Financial Overview
      9.4.3 Product Portfolio
      9.4.4 Business Strategies
      9.4.5 Recent Developments
9.5 Covance, Inc.
      9.5.1 Company Overview
      9.5.2 Financial Overview
      9.5.3 Product Portfolio
      9.5.4 Business Strategies
      9.5.5 Recent Developments
9.6 F. Hoffmann-La Roche Ltd.
      9.6.1 Company Overview
      9.6.2 Financial Overview
      9.6.3 Product Portfolio
      9.6.4 Business Strategies
      9.6.5 Recent Development
9.7 GlaxoSmithKline plc (GSK)
      9.7.1 Company Overview
      9.7.2 Financial Overview
      9.7.3 Product Portfolio
      9.7.4 Business Strategies
      9.7.5 Recent Developments
9.8 ICON plc
      9.8.1 Company Overview
      9.8.2 Financial Overview
      9.8.3 Product Portfolio
      9.8.4 Business Strategy
      9.8.5 Recent Developments
9.9 iGATE Corporation
      9.9.1 Company Overview
      9.9.2 FINANCIAL Overview
      9.9.3 Product Portfolio
      9.9.4 Business Strategies
      9.9.5 Recent Developments
9.10 iMEDGlobal Corporation
      9.10.1 Company Overview
      9.10.2 Financial Overview
      9.10.3 Product Portfolio
      9.10.4 Business Strategies
      9.10.5 Recent Developments
9.11 inVentiv Health, Inc.
      9.11.1 Company Overview
      9.11.2 Financial Overview
      9.11.3 Product Portfolio
      9.11.4 Business Strategies
      9.11.5 Recent Developments
9.12 Novartis International AG
      9.12.1 Company Overview
      9.12.2 Financial Overview
      9.12.3 Product Portfolio
      9.12.4 Business Strategies
      9.12.5 Recent Developments
9.13 PAREXEL International Corporation
      9.13.1 Company Overview
      9.13.2 Financial Overview
      9.13.3 Product Portfolio
      9.13.4 Recent Developments
9.14 Pfizer, Inc.
      9.14.1 Company Overview
      9.14.2 Financial Overview
      9.14.3 Product Portfolio      
      9.14.4 Business Strategies
      9.14.5 Recent Developments
9.15 Pharmaceutical Product Development, LLC. (PPD)
      9.15.1 Company Overview
      9.15.2 Financial Overview
      9.15.3 Product Portfolio
      9.15.4 Business Strategies
      9.15.5 Recent Developments
9.16 PRA Health Sciences, Inc.
      9.16.1 Company Overview
      9.16.2 Financial Overview
      9.16.3 Product Portfolio
      9.16.4 Business Strategies
      9.16.5 Recent Developments
9.17 Quintiles Transnational Holdings, Inc.
      9.17.1 Company Overview
      9.17.2 Financial Overview
      9.17.3 Product Portfolio
      9.17.4 Business Strategies
      9.17.5 Recent Developments
9.18 Sanofi
      9.18.1 Company Overview
      9.18.2 Financial Overview
      9.18.3 Product Portfolio
      9.18.4 Business Strategies
      9.18.5 Recent Developments
9.19 Synowledge LLC
      9.19.1 Company Overview
      9.19.2 Financial Overview
      9.19.3 Product Portfolio
      9.19.4 Business Strategies
      9.19.5 Recent Developments
9.20 Wipro Limited
      9.20.1 Company Overview
      9.20.2 Financial Overview
      9.20.3 Product Portfolio
      9.20.4 Business Strategies

List of Tables
 
TABLE 1 Market Snapshot : Pharmacovigilance Market
TABLE 2 Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2012 – 2020 (USD Million)
TABLE 3 Global Pharmacovigilance Market Revenue, by Type of Methods, 2012 – 2020 (USD Million)
TABLE 4 Global Pharmacovigilance Market Revenue, by Type of Service Providers, 2012 – 2020 (USD Million)
TABLE 5 Global Pharmacovigilance Market Revenue, by Geography, 2012 – 2020 (USD Million)

 

List of Figures
 
FIG. 1 Drug Safety From Molecule to Market
FIG. 2 Pharmacovigilance: Market Segmentation
FIG. 3 Global Pharmacovigilance Market, by Phases of Drug Development, 2013 (USD Million)
FIG. 4 Global Pharmacovigilance Market, by Type of Service Providers, 2013 (USD Million)
FIG. 5 Global Pharmacovigilance Market, by Type of Methods, 2013 (USD Million)
FIG. 6 Comparative Analysis: Global Pharmacovigilance Market, by Geography, 2103 (Value %)
FIG. 7 Porter’s Five Forces Analysis: Global Pharmacovigilance Market
FIG. 8 Market Attractiveness Analysis: Global Pharmacovigilance Market, by Geography (2013)
FIG. 9 Global Pharmacovigilance Market Share Analysis, by Key Players, 2013 (%)
FIG. 10 Safety Services : Product Lifecycle
FIG. 11 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Phases of Drug Development, 2013 & 2020 (Value %)
FIG. 12 Global Preclinical Studies Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 13 Global Phase I Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 14 Global Phase II Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 15 Global Phase III Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global Phase IV Clinical Trial Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Comparison of Methods: Pharmacovigilance reporting
FIG. 18 Comparative Analysis: Global Pharmacovigilance Market Revenue, by Type of Methods, 2013 & 2020 (Value %)
FIG. 19 Global Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Global Intensified ADR Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 21 Global Targeted Spontaneous Reporting Market Revenue, 2012 – 2020 (USD Million)
FIG. 22 Global Cohort Event Monitoring Market Revenue, 2012 – 2020 (USD Million)
FIG. 23 Global EHR Mining Market Revenue, 2012 – 2020 (USD Million)
FIG. 24 End-to-End Safety Across the Lifecycle
FIG. 25 Comparative Analysis: Global Pharmacovigilance Market, by Type of Service Providers, 2013 & 2020 (Value %)
FIG. 26 Global In-House Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 27 Global Contract Outsourcing Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 28 North America Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 29 Europe Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 30 Asia Pacific Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 31 RoW Pharmacovigilance Market Revenue, 2012 – 2020 (USD Million)
FIG. 32 Accenture plc.: Annual Revenue 2011– 2013 (USD Billion)
FIG. 33 Bristol-Myers Squibb: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 34 Cognizant Technology Solutions: Annual Revenue, 2011– 2013 (USD Million)
FIG. 35 COVANCE, Inc.: Annual Revenue, 2011– 2013 (USD Million)
FIG. 36 F. Hoffmann-La Roche Ltd., Annual Revenue: 2011 – 2013 (USD Million)
FIG. 37 GlaxoSmithKline plc (GSK): Annual Revenue, 2011 – 2013 (USD Million)
FIG. 38 ICON plc: Annual Revenue, 2011 – 2013 ( USD Million)
FIG. 39 iGATE Corporation: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 40 Novartis International AG: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 41 PAREXEL International Corporation: Annual Revenue 2011 – 2013 (USD Million)
FIG. 42 Pfizer, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 43 PRA Health Sciences, Inc., Annual Revenue: 2012 – 2014 (USD Million)
FIG. 44 Quintiles Transnational Holdings, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 45 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 46 Wipro Limited: Annual Revenue 2011 – 2013 (USD Million)

 

.